Team creates guidelines on CAR T-cell-related toxicity

Print Friendly, PDF & Email


Sattva Neelapu, MD
Photo courtesy of MD
Anderson Cancer Center
Researchers say they have created guidelines for managing the unique toxicities associated with chimeric antigen receptor (CAR) T-cell therapy. The guidelines focus on cytokine release syndrome (CRS); neurological toxicity, which the researchers have dubbed “CAR-T-cell-related encephalopathy syndrome (CRES);” and adverse effects related to... [Read Article]
Print Friendly, PDF & Email

Trials of atezolizumab placed on partial hold

Print Friendly, PDF & Email


Atezolizumab (Tecentriq)
Photo from Genentech
Roche has announced a partial clinical hold on 2 trials of the anti-PD-L1 antibody atezolizumab (Tecentriq). One is a phase 1b/2 study (NCT02631577) in which researchers are evaluating atezolizumab in combination with obinutuzumab plus lenalidomide in patients with relapsed or refractory follicular lymphoma. The other is a phase... [Read Article]
Print Friendly, PDF & Email

FDA approves drug to treat relapsed FL

Print Friendly, PDF & Email


Copanlisib (Aliqopa)
PRNewsfoto/Bayer
The US Food and Drug Administration (FDA) has granted accelerated approval to copanlisib (Aliqopa), an intravenous PI3K inhibitor developed by Bayer. The drug is now approved to treat adults with relapsed follicular lymphoma (FL) who have received at least 2 prior systemic therapies. Copanlisib received accelerated approval from the FDA... [Read Article]
Print Friendly, PDF & Email

Immune status linked to outcomes of CAR T-cell therapy

Print Friendly, PDF & Email


Micrograph showing DLBCL
Outcomes of treatment with a third-generation chimeric antigen receptor (CAR) T-cell therapy are associated with a patient’s immune status, according to a phase 1/2a trial. The CD19-specific CAR T-cell therapy produced a complete response (CR) in 6 of 15 patients with relapsed/refractory CD19-positive leukemia or lymphoma. Though all responders eventually... [Read Article]
Print Friendly, PDF & Email

Biosimilar deemed equivalent to reference drug in FL

Print Friendly, PDF & Email


Vials of drug
Photo by Bill Branson
The biosimilar GP2013 has demonstrated equivalence to its reference drug rituximab in patients with previously untreated, advanced-stage follicular lymphoma (FL), according to researchers. Treatment with GP2013 plus cyclophosphamide, vincristine, and prednisone (CVP) produced a similar overall response rate (ORR) as rituximab plus CVP in the phase... [Read Article]
Print Friendly, PDF & Email

CNS lymphoma responds to CAR T-cell therapy

Print Friendly, PDF & Email


Micrograph showing DLBCL
Researchers have reported the first known case of central nervous system (CNS) lymphoma responding to chimeric antigen receptor (CAR) T-cell therapy. The investigational CAR T-cell therapy JCAR017 induced complete remission of brain metastasis in a patient with refractory diffuse large-B-cell lymphoma (DLBCL). When a subcutaneous tumor began to recur 2... [Read Article]
Print Friendly, PDF & Email

Drug receives priority review for FL

Print Friendly, PDF & Email


Follicular lymphoma
The US Food and Drug Administration (FDA) has granted priority review to a supplemental biologics license application (sBLA) for obinutuzumab (Gazyva®). With this sBLA, Genentech is seeking approval for obinutuzumab to be used, first in combination with chemotherapy and then alone as maintenance, in patients with previously untreated follicular lymphoma (FL).... [Read Article]
Print Friendly, PDF & Email